Scoring treatment response in patients with relapsing multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 5, 2013, Pages 605-612

  Sormani, M P ^a   Rio, J ^b   Tintore M ^b   Signori, A ^a   Li, D ^c   Cornelisse, P ^d   Stubinski, B ^d   Stromillo, M L ^e   Montalban, X ^b   De Stefano, N ^e  

^a UNIVERSITY OF GENOA   (Italy)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MERCK SERONO S A   (Switzerland)

^e UNIVERSITY OF SIENA   (Italy)

Author keywords

Interferon; patient assessment; relapsing remitting multiple sclerosis; scoring system; treatment response

Indexed keywords

BETA1A INTERFERON;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; RECURRENCE RISK; SCORING SYSTEM; TREATMENT RESPONSE; VALIDATION STUDY;

EID: 84876546564     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512460605     Document Type: Article

References (13)

1. Río J, Nos C, Tintoré M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol. 2006 ; 59: 344-352
2. Freedman MS, Patry DG, Grand'Maison F, et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci. 2004 ; 31: 157-168
3. Rudick R, Lee J, Simon J, et al. Defining interferon β response status in multiple sclerosis patients. Ann Neurol. 2004 ; 56: 548-555
4. Rio J, Castillo J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon β in MS. Mult Scler. 2009 ; 15: 848-853
5. RIo J, Comabella M, Montalban X. Multiple sclerosis: Current treatment algorithms. Curr Op Neurol. 2011 ; 24: 230-237
6. Sormani MP, Li D, Bruzzi P, et al. Combined MRI lesions and relapses as a perfect surrogate for disability in multiple sclerosis. Neurol. 2011 ; 77: 1684-1690
7. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet. 1998 ; 352: 1498-1504
8. Prosperini L, Gallo V, Petsas N, et al. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol. 2009 ; 16: 1202-1209
9. Tomassini V, Paolillo A, Russo P, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol. 2006 ; 253: 287-293
10. Durelli L, Berbero P, Bergui M, et al. MRI activity and neutralizing antibody as predictor of response to IFNB treatment in MS. J Neurol Neurosurg Psychiatry. 2008 ; 79: 646-651
11. Noseworthy JH, Vandervoort MK, Wong CJ, et al. Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurol. 1990 ; 40: 971-975
12. Goodkin DE, Cookfair D, Wende K, et al. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurol. 1992 ; 42: 859-863
13. Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 1988 ; 111: 927-939